NCT06690112 Pilot Study for High Output Drainage Removal After Gastrectomy

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-01-01 with a primary completion date of 2025-06-30.

Brief Summary

\*Objective: The study aims to evaluate whether there is a difference in intra-abdominal complication rates between patients discharged with or without a drainage tube following gastrectomy with high postoperative drainage (≥300ml/day). \*Study Design: This is an open-label randomized controlled trial (RCT) involving two groups. Patients will be randomly assigned to either maintain the drainage tube (control) or have it removed (experimental) before discharge. The primary endpoint is the incidence of intra-abdominal complications within one month post-surgery. \*Participants: The study targets 60 patients (30 per group) who meet the following criteria: Diagnosed with gastric adenocarcinoma and underwent curative gastrectomy (R0 resection). Postoperative drainage of 300-500 ml/day on the 4th day after surgery. Patients with stage IV cancer, peritoneal metastasis, or postoperative complications requiring additional intervention are excluded. \*Methods: All participants will follow standard postoperative care except for the removal or retention of the drainage tube. Follow-up will occur at 1 and 3 weeks post-discharge, with clinical examinations and imaging (if necessary) to monitor for complications such as infection or abscess. The study's total observation period will last four weeks from the surgery date. \*Data Collection: Data will include patient demographics, surgical details, postoperative management, and the occurrence of complications. Drainage volumes will be recorded daily for those discharged with a tube, and tube removal will occur based on specific criteria.

Eligibility Criteria

Inclusion Criteria: * Patients pathologically diagnosed with gastric adenocarcinoma before surgery. * Patients eligible for complete surgical resection (R0 resection). * Patients with an ASA (American Society of Anesthesiologists) score of 3 or lower. * Patients with more than 300 ml of drainage in the 24 hours on the postoperative day 4. Exclusion Criteria: * Patients aged 80 or older. * Patients with stage IV gastric cancer. * Patients with ascites due to peritoneal metastasis. * Patients with evident intra-abdominal complications following surgery. * Patients who require the insertion of additional percutaneous drainage due to insufficient drainage. * Patients who underwent incomplete gastric resection (R1 or R2 resection). * Patients diagnosed with cancers other than gastric cancer. * Patients with a history of major intra-abdominal surgery or abdominal radiotherapy that may hinder the normal absorption of intra-abdominal fluid. * Patients with more than 500 ml of drainage in the 24 hours on postoperative day 4. * Patients presenting with any of the following clinical signs or diagnoses: 1. Postoperative pancreatic fistula (POPF), defined as drain amylase levels (Drain amylase; D-amy) more than 3 times higher than serum amylase levels (Serum amylase; S-amy). 2. Fever exceeding 37.8℃. 3. Presence of any of the following clinical markers of inflammation: i. White blood cell count (WBC) \> 15,000/μL ii. C-reactive protein \> 200 mg/L 4. Observation of non-serous drainage fluid, such as: i. Chylous fluid: Milky-colored fluid. ii. Bloody or sanguineous fluid: Intra-abdominal fluid suggestive of ongoing hemorrhage. * Vulnerable subjects will not be enrolled in the study, including minors, pregnant women, neonates, adults with impaired consent capacity, individuals in institutional facilities, students, employees of medical institutions or research centers, pharmaceutical company employees, military personnel, unemployed persons, impoverished individuals, homeless individuals, terminally ill patients, or patients in emergency situations.

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.